Medical Oncologist
AML mutation testing
FLT3 Mutation in AML: — Targeted Therapy and What to Expect
FLT3 is a gene mutation found in a substantial proportion of AML cases. When it is present, a class of targeted drugs called FLT3 inhibitors is added to your chemotherapy. Your mutation subtype — ITD or TKD — determines which drug your oncologist recommends.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Two subtypes with different risks — FLT3-ITD is associated with a higher relapse risk than FLT3-TKD. Which you have shapes your risk classification and treatment plan.
- A targeted drug class exists — FLT3 inhibitors work alongside chemotherapy — not instead of it. They block the protein that the FLT3 mutation activates.
- Testing is done at diagnosis — FLT3 status is checked from your bone marrow biopsy sample as a standard part of AML workup at diagnosis.
- The result affects transplant planning — For FLT3-ITD, whether and when to consider a stem cell transplant is a conversation that usually starts early in treatment planning.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
FLT3 is a gene mutation found in a substantial proportion of AML cases. When it is detected, NCCN and European LeukemiaNet guidance recommends adding an FLT3 inhibitor — a class of targeted drugs — to standard chemotherapy. Which drug is used depends on whether you have the ITD or TKD subtype and whether you are newly diagnosed or relapsed.
What is the FLT3 mutation and why does it change your treatment?
FLT3 is a gene that tells bone marrow cells when to grow and divide. When it mutates in AML, the signal gets stuck in the on position, causing leukaemia cells to multiply faster than they should.
Finding a FLT3 mutation changes your treatment. A class of drugs called FLT3 inhibitors is added to your chemotherapy to block that abnormal growth signal.
NCCN and European LeukemiaNet recommend FLT3 testing as a standard step at AML diagnosis, because the result directly determines which treatment regimen your oncologist will use.
What is the difference between FLT3-ITD and FLT3-TKD?
FLT3-ITD, or internal tandem duplication, is the more common subtype. It is associated with a higher risk of the leukaemia returning after treatment, and European LeukemiaNet classifies it as intermediate to adverse risk depending on the allelic ratio.
FLT3-TKD, or tyrosine kinase domain mutation, is less common and generally carries a lower relapse risk, though it still changes treatment planning when it is found.
Your test result will specify which subtype you have. If you have FLT3-ITD, your oncologist will also consider the allelic ratio — the proportion of abnormal FLT3 copies — which further refines your risk group.
How do FLT3 inhibitors fit into your chemotherapy?
FLT3 inhibitors are targeted drugs given in combination with standard induction chemotherapy, not as a replacement for it.
For newly diagnosed FLT3-mutated AML, NCCN guidelines include FLT3 inhibitors during induction and consolidation chemotherapy. Midostaurin and quizartinib are among the inhibitors used in this setting.
For AML that has returned after initial treatment, gilteritinib is used in the relapsed and refractory setting when a FLT3 mutation is confirmed. Your oncologist will specify which drug applies to your subtype and situation.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What do the terms on your test report mean?
- FLT3-ITD
- Internal tandem duplication. The more common FLT3 subtype, associated with higher relapse risk. European LeukemiaNet classifies it as intermediate or adverse depending on the allelic ratio.
- FLT3-TKD
- Tyrosine kinase domain mutation. Less common than ITD and generally carries a lower relapse risk. Still changes treatment planning when present.
- Allelic ratio
- The proportion of FLT3-ITD copies compared to normal copies in your leukaemia cells. A higher ratio is associated with a higher relapse risk and moves European LeukemiaNet classification toward adverse.
- Midostaurin
- An FLT3 inhibitor added to standard induction and consolidation chemotherapy for newly diagnosed FLT3-mutated AML, per NCCN and European LeukemiaNet guidance.
- Gilteritinib
- An FLT3 inhibitor used as a single agent for relapsed or refractory FLT3-mutated AML. The FLT3 mutation must be confirmed before it is started.
- Quizartinib
- An FLT3 inhibitor used alongside chemotherapy for newly diagnosed FLT3-ITD-positive AML. Eligibility is based specifically on the ITD subtype and depends on jurisdiction-level approval.
- ELN risk classification
- The European LeukemiaNet system that sorts AML into favourable, intermediate and adverse risk groups based on genetics and mutations. FLT3-ITD is classified as intermediate or adverse depending on allelic ratio.
Questions families ask about FLT3-mutated AML
Does having an FLT3 mutation mean my prognosis is poor?
FLT3-ITD is associated with a higher risk of relapse than some other AML subtypes, and European LeukemiaNet classifies it as intermediate or adverse risk. But prognosis in AML depends on more than one mutation. Your age, how quickly the leukaemia responds to the first round of chemotherapy, and other genetic findings all contribute. FLT3 mutation status is one piece of a larger picture, and the availability of FLT3 inhibitors has changed what that picture looks like compared to a decade ago, when the mutation was identified but there was nothing that specifically targeted it.
Does an FLT3 inhibitor replace any part of the chemotherapy?
No. FLT3 inhibitors are added to standard chemotherapy, not given instead of it. Standard induction chemotherapy remains the backbone of treatment. The inhibitor works alongside it by blocking the specific protein that the FLT3 mutation activates. Some families worry that adding a targeted drug means reducing chemotherapy — but that is not how the regimens are designed. The chemotherapy component stays the same.
Will a stem cell transplant be recommended?
For FLT3-ITD, transplant in first complete remission is considered for eligible patients, and NCCN guidance addresses this directly. Whether it is recommended for you depends on how you respond to induction chemotherapy, your age and overall fitness, and whether a suitable donor is available. This conversation typically starts early — often before induction is complete — so that the option is ready if you reach remission. Not every patient with FLT3-ITD will be a transplant candidate, and some do well without one.
What if the AML comes back after treatment?
If AML returns, your team will re-test for the FLT3 mutation, because mutation status can change between diagnosis and relapse. If an FLT3 mutation is confirmed at relapse, gilteritinib is among the drugs indicated in that setting per NCCN and European LeukemiaNet guidance. Transplant is also reconsidered in eligible patients who reach a second remission. What is available and appropriate will depend on what treatment you received the first time and how your leukaemia has behaved since.
Is FLT3 testing available in India?
Yes. FLT3 testing by next-generation sequencing or PCR is available at major diagnostic laboratories in India and is part of standard AML workup at centres following NCCN or ELN protocols. If testing was not done at your diagnosis, ask your oncologist whether a stored bone marrow sample can still be sent. Knowing your FLT3 status is useful even when it changes the conversation retrospectively, for example if transplant or maintenance therapy is now being discussed.
Are FLT3 inhibitors accessible to patients in India?
Midostaurin and gilteritinib are available in India, though access varies by centre and cost can be significant. Ask your oncologist specifically what is available at your treating centre, whether your insurance covers it, and whether patient assistance programmes apply. Quizartinib's availability in India is more limited — your team will tell you what applies to your specific subtype and situation.
Did you know?
For many years, FLT3-ITD was one of the most commonly detected mutations in AML and one of the harder subtypes to treat. Identifying it changed the risk classification on paper, but not the treatment itself.
The arrival of FLT3 inhibitors changed that. According to NCCN and European LeukemiaNet guidance, knowing your FLT3 status now directly determines what treatment you receive — not just how your risk is labelled.
Source: European LeukemiaNet Recommendations for Diagnosis and Management of Acute Myeloid Leukemia
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How is FLT3 testing done and how long does it take?
FLT3 testing is done on the bone marrow sample collected at diagnosis, so it does not usually need a separate procedure. The test uses next-generation sequencing or PCR and typically takes one to two weeks, though this varies by laboratory. Treatment planning sometimes begins before the result is back, with the regimen adjusted once mutation status is confirmed. Ask your oncologist when the sample was sent and when the result is expected, so you are not waiting without a timeline.
Can I have AML without an FLT3 mutation?
Yes, and most people with AML do not have an FLT3 mutation. AML is driven by many different genetic changes, and FLT3 is one of several tested routinely at diagnosis. If your result is negative, your treatment is shaped by the other mutations and characteristics in your bone marrow. Not having an FLT3 mutation is not in itself good or bad news — it means a different set of genetic findings will determine your treatment plan.
What does a high allelic ratio mean in plain terms?
The allelic ratio describes what proportion of your FLT3 gene copies carry the ITD mutation compared to normal copies. A higher ratio means a larger share of your leukaemia cells is driven by the abnormal signal. European LeukemiaNet uses this number to separate FLT3-ITD into intermediate and adverse risk groups. Your oncologist will tell you which category you fall into and what that means for decisions like whether to pursue a stem cell transplant.
Do FLT3 inhibitors cause serious side effects?
Like all cancer treatments, FLT3 inhibitors can cause side effects. Common ones include nausea, fatigue, and changes in blood counts — which can overlap with chemotherapy side effects and be difficult to separate. Some inhibitors are associated with heart rhythm changes, so your team will monitor with ECGs at intervals. The specific side effect profile differs between midostaurin, gilteritinib, and quizartinib, and your oncologist will explain what to watch for with the drug you are receiving.
What is measurable residual disease and does FLT3 help track it?
Measurable residual disease, or MRD, refers to small numbers of leukaemia cells that remain after treatment but are too few for a standard bone marrow examination to detect. FLT3 mutation can be used as an MRD marker — your team may test whether cells carrying the mutation are still detectable after chemotherapy. A positive MRD result is associated with a higher relapse risk and may influence decisions about transplant or maintenance therapy. Ask your oncologist whether MRD monitoring is being used in your case.
Are there clinical trials for FLT3-mutated AML in India?
Clinical trials testing newer FLT3 inhibitors and combinations are ongoing at several centres in India. Whether you are eligible depends on your specific subtype, prior treatment, and other clinical factors. Ask your oncologist at your next appointment whether any open trials apply to your situation. CTRI, the Clinical Trials Registry India, lists trials currently recruiting in India and is a resource your team can point you toward.